Abbott Laboratories faces a criminal investigation by the Justice Department, after its recall of formulas due to complaints of bacterial infections exacerbated a shortage that began due to pandemic-induced supply chain issues.
The Justice Department was investigating conduct at Abbott’s plant in Sturgis, Michigan,
According to an Abbott spokesman, they are fully cooperating with the Justice Department without specifying what aspect of the company is under scrutiny.
In February 2022, Abbott, the biggest US supplier of baby formula, recalled Similac and other infant formula products produced at its Michigan facility after reports of bacterial infections in babies who had consumed products made there.
The US Food and Drug Administration found "shocking" results during an inspection, such as cracks in vital equipment, inadequate hand-washing, and evidence of previous bacterial contamination.
The plant has since reopened.


California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
Supreme Court Tests Federal Reserve Independence Amid Trump’s Bid to Fire Lisa Cook
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Thailand Inflation Remains Negative for 10th Straight Month in January
Federal Judge Restores Funding for Gateway Rail Tunnel Project
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 



